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Background: Epilepsy is one of chronic neurological disorders that affects 0.5–1.0% of the world's population during their lifetime. There is a still significant need to develop novel anticonvulsant drugs that possess superior efficacy, broad spectrum of activities and good safety profile. 
Methods:α-asaronol and two current antiseizure drugs (α-asarone and carbamazepine (CBZ)) were assessed by in vivo anticonvulsant screening with the three most employed standard animal seizure models, including maximal electroshock seizure (MES), subcutaneous injection-pentylenetetrazole (PTZ)-induced seizures and 3- mercaptopropionic acid (3-MP)-induced seizures in mice. Considering drug safety evaluation, acute neurotoxicity was assessed with minimal motor impairment screening determined in the rotarod test, and acute toxicity was also detected in mice. 
Results:In our results, α-asaronol displayed a broad spectrum of anticonvulsant activity (ACA) and showed better protective indexes (PI = 11.11 in MES, PI = 8.68 in PTZ) and lower acute toxicity (LD50 =2940 mg/kg) than its metabolic parent compound (α-asarone). Additionally, α-asaronol displayed a prominent anticonvulsant profile with ED50 values of 62.02 mg/kg in the MES and 79.45 mg/kg in the sc-PTZ screen as compared with stiripentol of ED50 of 240 mg/kg and 115 mg/kg in the relevant test, respectively.
Conclusion:The results of the present study revealed α-asaronol can be developed as a novel molecular in the search for safer and efficient anticonvulsants having neuroprotective effects as well as low toxicity. Meanwhile, the results also suggested that α-asaronol has great potential to develop into another new aromatic allylic alcohols type anticonvulsant drug for add-on therapy of Dravet’s syndrome.
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Introduction
Epilepsy is one of chronic neurological disorders that affects 0.5–1.0% of the world's population during their lifetime [1,2]. Studies in the past two decades have demonstrated that many epilepsy treated with traditional Chinese medicines (TCM) has become attractive to patients as well as physicians in both Asian(especially in China) and Western countries [3]. The rhizome of Acorus tatarinowii (commonly known as “Shichangpu” in China) is officially listed in the Chinese Pharmacopoeia (2015ed) and has been commonly used by practitioners in the TCM for centuries for the treatment of neuronal disorders such as convulsions, epilepsy, coma, and senile dementia, etc.[4–8]. α-Asarone 1 ((E)-1-propenyl-2,4,5-trimethoxy-benzene, see Fig. 1), a major active component of A. tatarinowii, possess similar biological properties including neuroprotective, and especially sedative-hypnotics, anticonvulsant and/or anti-epilepsy effects [9–11]. In 1986, α-asarone had been made into an antiepileptic drugs (AEDs) (also known as “Xixinnao jiaonang”) in preventing seizures in China. Unfortunately, the drug therapy also has some side effects such as embryotoxicity and maternal toxicity, teratogenic, genotoxic and hepato-carcinogenic properties, and ataxia or muscle incoordination, and thus limit its clinical use [12–18]. Several studies attribute parts of these downside to the structure of propenylbenzene [19,20]. Therefore, it is imperative to develop new, high efficacy and less adverse effects of AEDs based on α-asarone.




Young adults male KunMing-strain mice weighing 22-28 g were used in this study. All the animals were kept under controlled environmental conditions (22±2 ℃; 50±20% humidity; 12 h light/darkcycle) with free access to pellet food and water. 
Drugs
PTZ was purchased from Alfa Aesar, Shanghai, China. Lot: 10180463; 3-MP was purchased from J&K Scientific Ltd., Beijing, China. Lot: LD50Q10; α-asarone (Xi’an Caijing Opto-Electrical Science & Technology Co., Ltd.) and CBZ (J&K Scientific Ltd., Beijing, China. Lot: LLA0P07) were used as reference anticonvulsant drugs for comparison. Both the reference drug and α-asaronol were dissolved in saline containing 0.5% Tween, and administrated orally (po) in a constant volume of 10 ml/kg. In our study, to prevent the results affected by observer preference, the tested compound and positive drugs treated in a double-blind way. In these experimental tests in the paper, the participants did not know which compound they administrated to the mice. Treatment groups were identified with letters like A, B. C, etc., and the investigator were blinded as to which letter denoted which of the treatment groups. 
Seizure models
Maximal electroshock seizure (MES) test
MES test were carried out according to previously described method [26]. Electro- convulsions were produced by an alternating current (0.25 s stimulus duration, 60 Hz, fixed current intensity of 50 mA) delivered via ear-clip electrodes by an electronic stimulator stimulator (SEN-3201) (Nihon Konden). Protection against the spread of MES-induced seizures was defined as the abolition of the tonic hind limb extension (hind limbs of animals outstretched 180° to the plain of the body). 54 mice were selected and randomly divided into vehicle, positive control and test groups. For the vehicle group, mice received normal saline. For the positive control group, mice received α-asarone (46 mg/kg, po) and CBZ (53 mg/kg, po). For the test groups, mice were respectively administrated orally with α-asaronol at 25, 36, 54, 80, 100 and 120 mg/kg. 0.25, 0.5, 1, 2, 3, and 4 h after the administration of the compounds all the mice were treated with electrical stimulation. Mice were considered protected if they did not exhibit tonic hind limb extension. Meanwhile, the anticonvulsant median effective dose (ED50) values of α-asaronol against the maximal electroshock-induced tonic hind limb extension was calculated by probit analysis.
Sc-PTZ-induced seizures
The anticonvulsant activities of α-asaronol was also carried out using the sc-PTZ-induced mice seizure model. Forty eight mice were randomly divided into 6 groups of eight mice each. Briefly, 25, 50, and 100 mg/kg α-asaronol was administrated orally for seven days to the mice, the control group received normal saline (10 ml/kg, po) and reference group received α-asarone (46 mg/kg, po) and CBZ (53 mg/kg, po). Sixty minutes after the last treatment, 85 mg/kg of freshly prepared solution of PTZ was administered subcutaneously to all the mice. Latent time for the onset, the percentage of incidence of tonic seizures, clonic seizures as well as the mortality rate were observed for 30 min after PTZ injection.
Sc-3-MP-induced seizures
The sc-3-MP-induced mice seizure model was adopted to evaluate the anticonvulsant activities of α-asaronol. Mice grouping and treatment of the animals were the same as for the PTZ test. Sixty minutes after the last treatment, 60 mg/kg of freshly prepared solution of 3-MP was administered subcutaneously to all the mice. Latent time for the onset, the percentage of incidence of tonic seizures, clonic seizures as well as the mortality protection were observed for 30 min after 3-MP injection.
Neurotoxicity test
The acute neurotoxicity of the α-asaronol, CBZ and α-asarone were measured in mice using the rotarod test. The mice were trained to place on a diameter 4 cm rod that rotates at 24 rpm. Then, trained mice were selected and randomly divided, and administrated orally with the different doses of the α-asaronol, as well as reference drugs so as to obtain the median neurotoxic dose (TD50). 0.5, 1, 2, and 3 h after drug treatment, each mice were placed on rotarod that rotates at 24 rpm. Neurologic toxicity is defined as the failure (drop more than 3 times from rotarod in 3 min) of the mice to remain on the rod for 3 min. TD50 was calculated by the probit method.
Acute toxicity test
The acute toxicity of α-asaronol and α-asarone were carried out as previously described [27]. The dose was increased from 100, 200, 400, 800, 1600, 3200 to 6400 mg/kg through the oral administration route. The animals were monitored successively for behavioral changes for the first 4 h, and then observed for signs of toxicity and mortality if any 24 h and daily for seven days after the drug administration. The 50% lethal dose (LD50) values was calculated by the Bliss method.
Statistical analysis




As can be seen from Table 1, the compound α-asaronol at 25 and 36 mg/kg had no marked anticonvulsant effects against MES-induced seizures. However, it showed significantly and dose-dependently anticonvulsant effects at 54, 80, 100, and 120 mg/kg, which offered 66.67%, 66.67%, 66.67% and 83.33% protections against tonic hind limb extension in 1h, respectively. Especially, the protected effect of the compound was basically the equivalent to that of CBZ at the same molar dose. While, the protected effect of α-asarone is not as good as α-asaronol at the same molar dose. The ED50 value of α-asaronol was 62.02 (41.72-87.6) mg/kg (Table 1).
Sc-PTZ-induced seizures test
From our study (Fig. 2), we can easily find that α-asaronol significantly and also dose dependently exhibited anticonvulsant effect against sc-PTZ-induced seizures by significant increasing the latency for the onset of seizure with 191.34 ± 33.16, 253.25 ± 54.13 and 309.33 ± 52.44 s, respectively at all the tested dose when compared with the saline group. Meanwhile, there was significant in decreasing the percentage of incidence of tonic seizures at 50 and 100 mg/kg. Also, α-asaronol offered 50%, 50%, and 100% protection against sc-PTZ-induced mortality at the dose of 25, 50, and 100 mg/kg, while CBZ (53 mg/kg) and α-asarone (46 mg/kg) produced 50% and 25% protection respectively. The ED50 value was 79.45 (49.17-187.74) mg/kg. Furthermore, in a same molar dose, the effects of α-asaronol (50 mg/kg) on sc-PTZ-induced tonic seizure rate and mortality rate were nearly comparable to that of CBZ (53 mg/kg), and clearly superior to that of α-asarone (46 mg/kg). 
Sc-3-MP-induced seizures test
As shown in Fig. 2, in the vehicle group, subcutaneously injection 3-MP (60 mg/kg) consistently induced tonic seizures, clonic seizures and death. Administration of α-asaronol, at doses of 25, 50, and 100 mg/kg significantly increased the time to the onset of seizures compared to that of vehicle control. At the same time, pretreatment the compound at the doses of 25, 50, and 100 mg/kg exhibited a 25%, 50%, and 100% protection respectively against tonic seizures, but failed to protect clonic seizures. Additionally, it also blocked the death of mice and decreased mortality as compared to vehicle control. In the same molar dose of 0.22 mmol/kg, α-asaronol offered 75% protection against sc-3-MP-induced mortality, whereas CBZ and α-asarone produced 75% and 50% protection.
Neurotoxicity test
In the rotarod test, all the trained mice remain on the rotarod for 180 s, when intragastric administration with α-asaronol of 200, 400 or 500 mg/kg, whereas from 600 to 1000 mg/kg group, mice dropped and showed neurotoxicity. Particularly, 1000 mg/kg treatment mice dropped immediately. The TD50 of α-asaronol was 689.34 (556.53-818.17) mg/kg, while the TD50 of the reference drug α-asarone and CBZ was 810.84 (668.12-1248.71) and 191.22 (117.54-594.99) mg/kg tested in the same conditions, respectively (Table 2).
Acute toxicity test
A lethal effect was neither observed after treatment of α-asaronol at doses of 100, 200, 400, and 800 mg/kg (data not shown). Food consumption trembling, body weight, piloerection and behavioral changes in laboratory mice remained unaffected during the observed period. However, mice death was found up to the highest doses tested 1600, 3200, and 6400 mg/kg, respectively. LD50 of α-asaronol in mice was 2940 mg/kg (2590 mg/kg-3460 mg/kg). LD50 of α-asarone was 549.58 (358.14-666.00) mg/kg (Table 2). Thus, α-asaronol are relatively low acute toxicity, and further study on sub-acute toxicity, chronic toxicity and physiological changes induced by this compound will be carried out.

Discussion
Although α-asarone as antiseizure drug has been used in China for about 30 years, this drug is not common in clinical treatment because of its toxicological properties. In Europe, α-asarone is still not regulated, but, in U.S., it is prohibited explicitly as additives in the food industry due to the lack of sufficient data for a risk assessment of α-asarone (21CFR189). Generally, the toxicity of α-asarone is regarded mainly coming from its propenylic section [31]. However, the precise pathogenicity mechanisms is still not clear. In a recent published article, Schrenk group uncovered that α-asarone has two different metabolic pathway in liver microsomes, which relate closely to the substrate concentration. They found that 3’-hydroxylation to form α-asaronol is dominate at low substrate concentrations, whereas the epoxidation pathway (leading to unstable (E)-and (Z)-asaron-1’, 2’-epoxide) tended to be more pronounced at high substrate concentrations. And the latter pathway were considered to be the key causes for various toxicity of α-asarone [21]. In this study, we have identified that the acute toxicity of α-asaronol (LD50 = 2940 mg/kg) was much less than that of α-asarone (LD50 = 549.58 mg/kg), while its anticonvulsant activities (MES, sc-PTZ and sc-3-MP model) increased obviously. These results implies that 3’-hydroxylation pathway of α-asarone is actually a self detoxifcation process and keeps back α-asarone’s anticonvulsant activities. Therefore, in comparison with administration of α-asarone, direct administration of α-asaronol to the experimental animal is an alternatively more effective way, which may avoid epoxidation pathway successfully and reduce corresponding toxicities. 
Furthermore, because of bearing a hydrophilic hydroxyl group, the water solubility of α-asaronol is apparently higher than that of α-asarone. Generally, the solubility is closely related to ClogP value, which is one of important factor influencing the drugs’ efficacy. After investigation of 257-marketed CNS drugs with relatively favorable anticonvulsant activity, Jezequel showed that the optimal ClogP values of these drugs varied between 1 and 2 [32]. Thus, we compared the ClogP values of α-asaronol, α-asarone and CBZ (Table 3) and found that the ClogP value of α-asaronol (1.2581) just fall in the range between 1 and 2. In fact, this theoretical prediction is basically consistent with our experimental data, namely, ACAα-asaronol ≈ ACACBZ > ACAα-asarone (see Table 1, Table 2 and Fig. 2). This clearly indicates that 3’-hydroxy group plays a vital role to the structure of α-asarone both in physicochemical and biological properties. 
However, the hydroxyl group on the α-asaronol brings far more benefit than those listed above. In comparison with α-asarone, in a same molar dose, the anticonvulsant potential were clearly superior to that of its precursor compound α-asarone in the broad spectra of activity across the commonly used seizure tests-MES, PTZ and 3-MP. Briefly, the compound has an ED50 of 62.02 mg/kg and higher protective index (PI = 11.11) than that of α-asarone (PI < 8.11) in the MES test. Both in the sc-PTZ and sc-3-MP tests, in addition to observably prolong the incubation period for fore leg clonus, α-asaronol partially inhibited the tonic seizures and reduced lethality compared with that of α-asarone. Through the selected animal models, tool medicine and the reported antiepileptic mechanism of α-asarone, we speculate that α-asaronol exerts antiepileptic effect by enhancing GABAergic neurotransmission and/or blockade of glutamatergic neurotransmission mediated by NMDA receptor in mice brain. 
Interestingly, the structure of α-asaronol is partly similar to that of stiripentol (STP), which is structurally unrelated to any other conventional AEDs. They both have the ether bond (methyl ether or methylene ether) and aromatic propenylic hydroxy moiety in their skeleton. Up to now, STP was granted as the only orphan drug by European Medicines Agency (EMA) in 2001 (designation number EU/3/01/071) and approved as adjunctive therapy for Dravet syndrome (also called severe myoclonic epilepsy of infancy) in Europe in 2007, and in Japan and Canada in 2012. It has many unique activities such as increasing GABA transmission [33] and inhibition of lactic dehydrogenase (LDH) [34]. However, due to hydrophobic tertiary butyl group in the C-3’ position, stiripentol has low solubility in water (ClogP = 3.209, Table 3) and exhibits relatively low bioavailability. It is 99% bound to plasma proteins [35,36]. In contrast, as already mentioned, α-asaronol exhibited proper water solubility and good bioavailability. Additionally, α-asaronol displayed a promising anticonvulsant profile with ED50 = 79.45 (49.17-187.74) mg/kg as compared with stiripentol (ED50=115 mg/kg [37]) in the sc-PTZ screen. So, we anticipate that α-asaronol or some of its derivatives could well be developed to generate next AED with the same or better curative effect as STP.
In summary, we have firstly reported in this study on α-asaronol possessing pronounced anticonvulsant activity in the MES, sc-PTZ, and sc-3-MP-induced seizures in mice. It's promising to be developed as a new, potent, and safe antiepileptic agent in the future. Moreover, the results also suggested that the introduction of relatively small, electron-rich hydroxy group at the C-3’ position in α-asarone was beneficial for anticonvulsant activity. This also provided us a good clues for designing other potential anticonvulsant compounds. And further modification of the chemical structure and unraveling significance mechanism of α-asaronol for in vivo anticonvulsant activity in various seizure models is currently underway and will be reported in due course.
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